- Home
- ACAD vs SID Comparison
ACAD vs SID Comparison
Compare ACAD & SID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SID
- Stock Information
- Founded
- ACAD 1993
- SID 1941
- Country
- ACAD United States
- SID Brazil
- Employees
- ACAD N/A
- SID N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SID Steel/Iron Ore
- Sector
- ACAD Health Care
- SID Industrials
- Exchange
- ACAD Nasdaq
- SID Nasdaq
- Market Cap
- ACAD 3.8B
- SID 1.9B
- IPO Year
- ACAD 2004
- SID 1997
- Fundamental
- Price
- ACAD $20.95
- SID $1.55
- Analyst Decision
- ACAD Buy
- SID Strong Sell
- Analyst Count
- ACAD 19
- SID 1
- Target Price
- ACAD $27.89
- SID $1.30
- AVG Volume (30 Days)
- ACAD 2.0M
- SID 3.1M
- Earning Date
- ACAD 08-05-2025
- SID 07-31-2025
- Dividend Yield
- ACAD N/A
- SID 13.51%
- EPS Growth
- ACAD N/A
- SID N/A
- EPS
- ACAD 1.37
- SID N/A
- Revenue
- ACAD $996,283,000.00
- SID $7,828,045,151.00
- Revenue This Year
- ACAD $13.39
- SID $7.14
- Revenue Next Year
- ACAD $10.59
- SID $3.79
- P/E Ratio
- ACAD $15.31
- SID N/A
- Revenue Growth
- ACAD 22.42
- SID 2.40
- 52 Week Low
- ACAD $13.40
- SID $1.27
- 52 Week High
- ACAD $25.23
- SID $2.50
- Technical
- Relative Strength Index (RSI)
- ACAD 45.89
- SID 56.55
- Support Level
- ACAD $21.16
- SID $1.36
- Resistance Level
- ACAD $23.09
- SID $1.45
- Average True Range (ATR)
- ACAD 0.77
- SID 0.05
- MACD
- ACAD -0.32
- SID 0.01
- Stochastic Oscillator
- ACAD 0.47
- SID 96.00
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.